Beyond VEGF: targeting tumor growth and angiogenesis via alternative mechanisms.
Christensen
James
J
Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, La Jolla, CA 92121, USA. james.christensen@pfizer.com
Anderes
Kenna
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D000071877:Checkpoint Kinase 1; D002626:Chemistry, Pharmaceutical / Q000639:trends; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*; D009389:Neovascularization, Pathologic; D011494:Protein Kinases / Q000737:chemistry; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism* / Q000502:physiology
D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D011494:Protein Kinases; D019859:Proto-Oncogene Proteins c-met; D000071877:Checkpoint Kinase 1